ARTICLE | Strategy

Passing the baton

Challenges and opportunities for Novartis’ CEO designate Narasimhan

September 16, 2017 4:12 AM UTC

When he takes the helm as CEO of Novartis AG in January, Vasant Narasimhan will inherit a business that is still struggling to plug the revenue hole from cancer drug Gleevec imatinib going off patent in February 2016.

The pharma’s big bet on heart failure drug Entresto sacubitril/valsartan, launched in 2015, is dogged by slow uptake, and the Alcon Inc. eye care business fully acquired in 2011 is declining...

BCIQ Company Profiles

Novartis AG